Drug intelligence / Profile preview

GSK2788723

Development stage: Unknown
Lead developer: GSK
Modality: Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

GSK2788723 is an investigational drug developed for the treatment of Hunter syndrome (also known as mucopolysaccharidosis type II, MPS II), a rare lysosomal storage disorder. The drug has been studied in clinical trials to assess potential cross-reactivity with idursulfase, another enzyme replacement therapy used for Hunter syndrome. GSK2788723 is being developed by JCR and GSK[2][7]. Its precise mechanism of action is not detailed in the available sources, but it is likely related to enzyme replacement or modification therapy targeting the underlying enzymatic deficiency characteristic of MPS II.

Beyond the preview

Go deeper on GSK2788723.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2788723.

Explore the full profile